AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10521999
Drug: 3-day intravenous
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day intravenous omeprazole (80 mg loading then 40 mg q 9 am & 9 pm) plus ampicillin/salbactum (1.5 gm i.v. loading then 750 mg q 9 am, 3 pm, & 9 pm)
Trial: 10521999
Drug: 3-day intravenous
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day intravenous omeprazole (80 mg loading then 40 mg q 9 am & 9 pm) plus metronidazole and erythromycin (both 500 mg i.v. q 9 am, 3 pm, & 9 pm)
Trial: 10521999
Drug: 3-day intravenous
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day intravenous omeprazole (80 mg loading then 40 mg q 9 am & 9 pm) plus erythromycin (both 500 mg i.v. q 9 am, 3 pm, & 9 pm)
Trial: 10521999
Drug: Oral dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dual therapy (omeprazole 20 mg and amoxycillin 1 g bid x 2 weeks)
Trial: 10521999
Drug: 3-day intravenous
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day intravenous regimens (Groups 1-3)
Trial: 7491890
Drug: 130 g
RxNorm normalized name: ISOPROPYL ALCOHOL 1130 g in 400 TOPICAL CLOTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 130 g dry lentils/d
Trial: 1791775
Drug: Control (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (50 mg oestradiol implant)
Trial: 6754212
Drug: Levonantradol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonantradol 0.5 mg
Trial: 6754212
Drug: Levonantradol 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonantradol 0.75 mg
Trial: 6754212
Drug: Chlorpromazine 26
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine 26 mg
Trial: 19732445
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group receiving 500 mg medicinal starch daily
Trial: 19732445
Drug: GTP group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTP group receiving 500 mg of GTP per day
Trial: 19732445
Drug: Placebo+TC group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo+TC group receiving both placebo treatment and TC training (60‐minute group exercise, 3 times per week)
Trial: 10667742
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of risperidone or haloperidol (maximum, < or = 6 mg/day)
Trial: 25663
Drug: Lorazepam 2
RxNorm normalized name: lorazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 2 mg alone
Trial: 25663
Drug: Lorazepam 4
RxNorm normalized name: lorazepam 4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 4 mg alone
Trial: 25663
Drug: Lorazepam 2
RxNorm normalized name: lorazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 2 mg + Atropine 0.4 mg + Hyoscine 0.4 mg
Trial: 25663
Drug: Lorazepam 4
RxNorm normalized name: lorazepam 4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 4 mg + Atropine 0.4 mg + Hyoscine 0.4 mg
Trial: 30106348
Drug: 24-hour metformin
RxNorm normalized name: metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 24-hour metformin discontinuation
Trial: 30106348
Drug: 48-hour metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48-hour metformin discontinuation
Trial: 30106348
Drug: No metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No metformin discontinuation (control)
Trial: 26577455
Drug: 0.1 mm
RxNorm normalized name: gadobenate dimeglumine 529 mg/mL (0.1 mmol/0.2 mL) INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mm MAL cream
Trial: 26577455
Drug: 0.2 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mm MAL cream
Trial: 26577455
Drug: 0.4 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mm MAL cream
Trial: 26577455
Drug: 1.0 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mm MAL cream
Trial: 22397710
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional modality treatments only)
Trial: 12370681
Drug: Remifentanil infusion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion, BIS-titrated
Trial: 7478084
Drug: GnRH Analogues
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH Analogues therapy
Trial: 7478084
Drug: GnRH Analogues
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH Analogues therapy with Ipriflavone
Trial: 6112998
Drug: Gallamine 10
RxNorm normalized name: gallamine
DrugBank: Gallamine (DB13584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gallamine 10 mg
Trial: 6112998
Drug: Gallamine 20
RxNorm normalized name: gallamine 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallamine 20 mg
Trial: 6112998
Drug: Tubocurarine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tubocurarine 5 mg
Trial: 6112998
Drug: Pancuronium 1
RxNorm normalized name: pancuronium 1 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 1 mg
Trial: 31999335
Drug: Systemic antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotic prophylaxis (SAP) for 2 to 14 days after admission
Trial: 31999335
Drug: Systemic antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotic prophylaxis (SAP)
Trial: 31786720
Drug: Patients on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on ≥ 4 drugs
Trial: 31786720
Drug: Patients at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients at risk of serious or very serious drug interactions
Trial: 31786720
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between number of drugs taken and risk of serious or very serious interaction
Trial: 27258567
Drug: Novel triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel triple IHC antibody cocktail (TNP) composed of TTF1, Napsin A, and p40.
Trial: 27699179
Drug: Medtable™ medication-planning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medtable™ medication-planning tool
Trial: 25027101
Drug: OMEGA‐3 polyunsaturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMEGA‐3 polyunsaturated fatty acids (200 mg/kg/day starting before anesthesia induction for 24 hours followed by 100 mg/kg/day for 7 days)
Trial: 18936475
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa (IFN) monotherapy
Trial: 8644655
Drug: c7E3 bolus
RxNorm normalized name: c7E3
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: c7E3 bolus and infusion
Trial: 6391391
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution without bicarbonate
Trial: 6391391
Drug: World Health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: World Health Organisation oral rehydration solution (control)
Trial: 22300423
Drug: Varenicline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (1 mg twice daily)
Trial: 29112461
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and Vitamin D supplementation (1250 mg calcium carbonate and 400 IU vitamin D3)
Trial: 25291126
Drug: Lactobacilli supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacilli supplementation (L. rhamnosus LR06, L. pentosus LPS01, L. plantarum LP01, L. delbrueckii subsp. delbrueckii LDD01) for 15 days
Trial: 21058198
Drug: Oral formula
RxNorm normalized name: L-Formula Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formula with nutrients arginine, RNA, and ω‐3 fatty acids (Group 2)
Trial: 11898769
Drug: Low-energy diet
RxNorm normalized name: Low-energy diets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy diet with semi-solid meals (2.5 g guar gum)
Trial: 2697886
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with ispaghula husk and propantheline (Group B)
Trial: 2697886
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment after relapse on placebo
Trial: 2697886
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of active treatment
Trial: 2697886
Drug: Reinstitution of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinstitution of active treatment
Trial: 973598
Drug: Pure ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pure ethanol (9.3% w/v aqueous alcohol solution)
Trial: 24117692
Drug: 10-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day sequential therapy (omeprazole and amoxicillin for 5 days followed by omeprazole, clarithromycin and metronidazole for 5 days)
Trial: 24117692
Drug: 7-day standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day standard triple therapy (omeprazole, amoxicillin and clarithromycin)
Trial: 24117692
Drug: 10-day standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day standard triple therapy (omeprazole, amoxicillin and clarithromycin)
Trial: 16373409
Drug: HCG group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCG group (vaginal progesterone after HCG administration)
Trial: 14626871
Drug: Maximum recommended
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum recommended dose of mepivacaine
Trial: 8618582
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg famotidine twice daily
Trial: 28141622
Drug: Avisetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avisetron (8 mg)
Trial: 26556032
Drug: Online program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online program plus weekly email prompts
Trial: 24180166
Drug: Licorice lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licorice lozenges (Group A)
Trial: 21470071
Drug: Zaltoprofen (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaltoprofen (80 mg t.i.d.)
Trial: 19447425
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (300 mg orally daily)
Trial: 14706765
Drug: Low-dose synthetic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose synthetic conjugated estrogens A (SCE-A), 0.3 mg once daily for 16 weeks
Trial: 14706765
Drug: Low-dose synthetic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose synthetic conjugated estrogens A (SCE-A)
Trial: 7758607
Drug: Digoxin in
RxNorm normalized name: digoxin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin in combination with diuretics
Trial: 7758607
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of digoxin and diuretics with a blocker of the renin‐angiotensin system (kapothenum)
Trial: 3058101
Drug: 2% MK-927
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% MK-927 ophthalmic solution
Trial: 25873370
Drug: Polyphenon E
RxNorm normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyphenon E (PolyE) - 400 mg (‐)‐epigallocatechin‐3‐gallate (EGCG) per day
Trial: 23792649
Drug: Low-dose Tacrolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Tacrolimus QD
Trial: 21296768
Drug: Intercostal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal nerve block plus i.v. patient-controlled analgesia with morphine
Trial: 19795984
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with facial fillers (poly‐l‐lactic acid or polyacrylamide gel)
Trial: 19795984
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment with facial fillers (poly‐l‐lactic acid or polyacrylamide gel)
Trial: 12563891
Drug: Intranasal capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal capsaicin (3 x 10(‐6) mol, dissolved in 70% ethanol)
Trial: 3532742
Drug: Intravenous plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous plus intracoronary SK
Trial: 3532742
Drug: Successful recanalization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful recanalization during intracoronary SK infusion
Trial: 3532742
Drug: Persistent coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persistent coronary occlusion despite thrombolytic therapy
Trial: 15849974
Drug: Drug treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatments for acute manic or depressive episodes
Trial: 11818112
Drug: 15 days
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 days of 50 microg/day transdermal 17beta‐estradiol (TE) administration
Trial: 11818112
Drug: 15 days
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 days of 100 microg/day transdermal 17beta‐estradiol (Estraderm‐Ciba) administration
Trial: 10385059
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (colloidal bismuth subcitrate, tetracycline, metronidazole) for 2 weeks
Trial: 10385059
Drug: Sucralphate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralphate (1 g, q.i.d.) for 4 weeks
Trial: 10385059
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg, b.d.) for 4 weeks
Trial: 6123330
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bunitrolol (BU)
Trial: 6123330
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg methypranol (ME)
Trial: 31308556
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Intense Pulse Light and topical eflornithine therapy (topical eflornithine applied twice a day and IPL session once a month for 6 months)
Trial: 31308556
Drug: Intense Pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intense Pulse Light therapy alone (IPL monthly sessions for 6 months)
Trial: 28372653
Drug: 20ml of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20ml of 0.75% ropivacaine with 1ml of isotonic saline and intravenous 4mg dexamethasone (Div group, n=20)
Trial: 23525419
Drug: 7-day IPC
RxNorm normalized name: CAP,IPC VALVE ROCKET #54410
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day IPC (single daily episodes of IPC for 6 days prior to IR)
Trial: 23525419
Drug: Celecoxib (cyclooxygenase‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (cyclooxygenase‐2 inhibitor)
Trial: 21489168
Drug: Standard concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard concentration intranasal fentanyl (SINF)
Trial: 21489168
Drug: Highly concentrated
RxNorm normalized name: Recombinant human highly phosphorylated acid alpha-glucosidase
DrugBank: Recombinant human highly phosphorylated acid alpha-glucosidase (DB17673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly concentrated intranasal fentanyl (HINF)
Trial: 17230032
Drug: Escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 or 20 mg/day
Trial: 7606728
Drug: Deoxyspergualin (DSG)
RxNorm normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deoxyspergualin (DSG) at doses of 50 mg/m2 (dl I) or 150 mg/m2 (dl II and III) administered on days 1-7.
Trial: 7606728
Drug: L6 mAb
RxNorm normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L6 mAb administered at a fixed dose of 200 mg/m2 on days 1-5.
Trial: 7606728
Drug: Deoxyspergualin (DSG)
RxNorm normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deoxyspergualin (DSG) at a starting dose of 150 mg/m2/day recommended for Phase II trials.
Trial: 30485123
Drug: Mindfulness-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based treatment protocol
Trial: 28027630
Drug: SQ-LNSs (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ-LNSs (20 g daily)
Trial: 28027630
Drug: Biscuit (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biscuit (3 pieces daily)
Trial: 17690809
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg alcohol (Experiment 1)
Trial: 17690809
Drug: 0.7 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 g/kg alcohol (Experiment 2)
Trial: 15637138
Drug: 4-drug induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-drug induction treatment with intermediate-dose cytarabine and mitoxantrone salvage treatment
Trial: 15637138
Drug: Initial induction
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial induction treatment
Trial: 10431340
Drug: Mouth rinse
RxNorm normalized name: Ulcerease 0.6 % Mouth Rinse
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouth rinse containing amyloglucosidase and glucose oxidase (enzyme solution)
Trial: 7648979
Drug: Bile acid
RxNorm normalized name: Bile acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bile acid medication with or without shock‐wave lithotripsy
Trial: 28236619
Drug: Acupuncture adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture adjunctive to zolpidem (AAZ)
Trial: 28236619
Drug: Biofeedback adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback adjunctive to zolpidem (BAZ)
Trial: 24315664
Drug: 5% CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% CO2 inhalation during hyperventilation
Trial: 19444092
Drug: Ranolazine 1000
RxNorm normalized name: ranolazine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine 1000 mg twice daily for 6 weeks
Trial: 15064019
Drug: 0.5Gy once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5Gy once daily
Trial: 11925292
Drug: Haloperidol decanoate
RxNorm normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol decanoate 200 mg
Trial: 11925292
Drug: Haloperidol decanoate
RxNorm normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol decanoate 100 mg
Trial: 11925292
Drug: Haloperidol decanoate
RxNorm normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol decanoate 50 mg
Trial: 11925292
Drug: Haloperidol decanoate
RxNorm normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol decanoate 25 mg
Trial: 326349
Drug: Ornidazole 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornidazole 1.5 g single dose
Trial: 29958053
Drug: Curcumin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (1 g/d)
Trial: 21592308
Drug: Oseltamivir 75
RxNorm normalized name: oseltamivir 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 75 mg (evening dose) on day 3, followed by 75 mg b.i.d. on day 4
Trial: 17000801
Drug: Remifentanil high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil high concentration (8 ng mL(‐1))
Trial: 17000801
Drug: Remifentanil low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil low concentration (3 ng mL(‐1))
Trial: 10969252
Drug: DTaP-HBV-IPV/Hib (mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-HBV-IPV/Hib (mixed administration)
Trial: 10969252
Drug: DTaP-HBV-IPV +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-HBV-IPV + Hib (separate administration)
Trial: 10969252
Drug: Both mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both mixed and separate administration
Trial: 1386029
Drug: Goserelin (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (3.6 mg depot monthly subcutaneously)
Trial: 1386029
Drug: Danazol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (200 mg three times a day for 24 weeks)